Clinical studies for CNS drugs have a much lower success rate for FDA approval than non-CNS drugs (6.2% vs 13.3%). Patient recruitment can also be challenging and costly. For Alzheimer’s drug studies, the screen failure rate in at-risk populations is typically 70-75%. ViewMind technology can help you speed up your screening, reduce its costs, ensure cohorts are cognitively matched, and measure the impact of new drugs.
ViewMind can reduce screen failure rates by more than 50% with a non-invasive, 15-minute pre-screening for better cohort harmonization and stratification that will boost the statistical significance of the results.
ViewMind can give you access to critical, frequently updated, individualized data to complement pathological biomarker results, so that you can achieve better patient outcomes.
“ViewMind’s technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition. ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology.
The company’s offering spans the diagnostic continuum, from early stage to disease progression, monitoring, response, and treatment.”
Assess brain health by cognitive domain through a non-invasive, scalable and accurate pre-screening.
Identify patients for treatment and frequently measure treatment progress throughout your clinical trial with an objective, scalable solution.
Improve patient cohort harmonization, stratification and the statistical significance of clinical studies.
Measure the impact of a drug or a digital therapeutic on different cognitive domains of clinical trial participants.
ViewMind works in people independent of age, educational levels, and cultural background.
Run inclusive studies that address diverse communities and healthcare disparities.
Measure individual patient response to treatment and monitor progress in short time intervals.
Use a scalable, non-invasive test combined with precision cognition measurement.
Identify early subclinical disease and its progression.
Brain Health for Life
Easy to perform. Non-invasive.
Precision Neurology.
© Copyright Viewmind 2018 – 2024 | All rights reserved | Designed by SNTRIX
This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
If you have questions about the interpretation of your results, please consult with your healthcare provider.